Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study.
Sibyl WrayFrancois H JacquesTamara A MillerJacqueline A NicholasRafael ArroyoLori TravisBhupendra KhatriMagdalena ChirieacRoopali GandhiNora RoeschAmelie RodriguesLydie Melas-MeltAndreea M RawlingsSamuel F HunterPublished in: Multiple sclerosis journal - experimental, translational and clinical (2022)
The primary endpoint was met; the safety of alemtuzumab was consistent with pivotal studies.